BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
ADVERSE O
REACTIONS O
INCLUDING O
TENDINITIS O
, O
TENDON O
RUPTURE O
, O
PERIPHERAL O
NEUROPATHY O
, O
CENTRAL O
NERVOUS O
SYSTEM O
EFFECTS O
AND O
EXACERBATION O
OF O
MYASTHENIA O
GRAVIS O
WARNING O
: O
SERIOUS O
ADVERSE O
REACTIONS O
INCLUDING O
TENDINITIS O
, O
TENDON O
RUPTURE O
, O
PERIPHERAL O
NEUROPATHY O
, O
CENTRAL O
NERVOUS O
SYSTEM O
EFFECTS O
AND O
EXACERBATION B-OSE_Labeled_AE
OF I-OSE_Labeled_AE
MYASTHENIA I-OSE_Labeled_AE
GRAVIS I-OSE_Labeled_AE
* O
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
been O
associated O
with O
disabling O
and O
potentially O
irreversible O
serious O
adverse O
reactions O
that O
have O
occurred O
together O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
, O
including O
: O
Tendinitis B-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
Central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Discontinue O
LEVAQUIN O
immediately O
and O
avoid O
the O
use O
of O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
in O
patients O
who O
experience O
any O
of O
these O
serious O
adverse O
reactions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
may O
exacerbate B-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
in O
patients O
with O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
. O

Avoid O
LEVAQUIN O
( O
r O
) O
in O
patients O
with O
a O
known O
history O
of O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Because O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
serious O
adverse O
reactions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1-5.14 O
) O
] O
, O
reserve O
LEVAQUIN O
for O
use O
in O
patients O
who O
have O
no O
alternative O
treatment O
options O
for O
the O
following O
indications O
: O
Uncomplicated O
urinary B-Not_AE_Candidate
tract I-Not_AE_Candidate
infection I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.12 O
) O
] O
Acute B-Not_AE_Candidate
bacterial I-Not_AE_Candidate
exacerbation I-Not_AE_Candidate
of I-Not_AE_Candidate
chronic I-Not_AE_Candidate
bronchitis I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.13 O
) O
] O
Acute B-Not_AE_Candidate
bacterial I-Not_AE_Candidate
sinusitis I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.14 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
SERIOUS O
ADVERSE O
REACTIONS O
INCLUDING O
TENDINITIS O
, O
TENDON O
RUPTURE O
, O
PERIPHERAL O
NEUROPATHY O
, O
CENTRAL O
NERVOUS O
SYSTEM O
EFFECTS O
AND O
EXACERBATION O
OF O
MYASTHENIA O
GRAVIS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
been O
associated O
with O
disabling O
and O
potentially O
irreversible O
serious O
adverse O
reactions O
that O
have O
occurred O
together O
( O
5.1 O
) O
, O
including O
: O
* O
Tendinitis O
and O
tendon O
rupture O
( O
5.2 O
) O
* O
Peripheral O
neuropathy O
( O
5.3 O
) O
* O
Central O
nervous O
system O
effects O
( O
5.4 O
) O
Discontinue O
LEVAQUIN O
immediately O
and O
avoid O
the O
use O
of O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
in O
patients O
who O
experience O
any O
of O
these O
serious O
adverse O
reactions O
( O
5.1 O
) O
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
may O
exacerbate O
muscle O
weakness O
in O
patients O
with O
myasthenia O
gravis O
. O

Avoid O
LEVAQUIN O
( O
r O
) O
in O
patients O
with O
a O
known O
history O
of O
myasthenia O
gravis O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Because O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
serious O
adverse O
reactions O
( O
5.1-5.14 O
) O
, O
reserve O
LEVAQUIN O
for O
use O
in O
patients O
who O
have O
no O
alternative O
treatment O
options O
for O
the O
following O
indications O
: O
* O
Uncomplicated O
urinary O
tract O
infection O
( O
1.12 O
) O
* O
Acute O
bacterial O
exacerbation O
of O
chronic O
bronchitis O
( O
1.13 O
) O
* O
Acute O
bacterial O
sinusitis O
( O
1.14 O
) O

